Do you want to read an article? Please log in or register.
The effect of treatments for rheumatoid arthritis on endothelial dysfunction evaluated by flow-mediated vasodilation in patients with rheumatoid arthritis
Rheumatoid Arthritis
Related content
Rheumatoid Arthritis
Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction, NETosis, and inflammation
Transl Res.
Ruiz-Limón P, Ortega R, Arias de la Rosa I, Abalos-Aguilera MDC, Perez-Sanchez C, Jimenez-Gomez Y, Peralbo-Santaella E, Font P, Ruiz-Vilches D, Ferrin G, Collantes-Estevez E, Escudero-Contreras A, López-Pedrera C, Barbarroja N
doi: 10.1016/j.trsl.2016.12.003.
Rheumatoid Arthritis
Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry
Rheumatol Ther.
Pappas DA, Kremer JM, Griffith J, Reed G, Salim B, Karki C, Garg V
doi: 10.1007/s40744-017-0077-z.
T CellsRheumatoid Arthritis
Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis
Rheumatology (Oxford).
Ramwadhdoebe TH, van Baarsen LGM, Boumans MJH, Bruijnen STG, Safy M, Berger FH, Semmelink JF, van der Laken CJ, Gerlag DM, Thurlings RM, Tak PP
doi: 10.1093/rheumatology/key428.
Rheumatoid Arthritis
The 20 year outcome and association between early treatment and mortality and disability in an inception cohort of patients with rheumatoid arthritis: Results from the Norfolk Arthritis Register
Arthritis Rheumatol.
Gwinnutt JM, Symmons DP, MacGregor AJ, Chipping JR, Marshall T, Lunt M, Verstappen SM
doi: 10.1002/art.40090.
Rheumatoid Arthritis
Effects of Sarilumab on Patient-Reported Impact of Rheumatoid Arthritis Using the Rheumatoid Arthritis Impact of Disease Scale
J Rheumatol.
Gossec L, Strand V, Proudfoot C,
Chen CI, Guillonneau S, Kimura T, van Hoogstraten H, Mangan E, Reaney M
doi: 10.3899/jrheum.180904.
COMMENTED
Rheumatoid Arthritis
Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs
★ 3
Recommended and commented by
Dr Heino Prillwitz, Faculty Member
doi: 10.1186/s13075-019-2059-8.
Melanoma and Skin CancerRheumatoid Arthritis
Baricitinib, Methotrexate, or Combination in Patients with Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment
Arthritis Rheumatol.
Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M, Zerbini CA, Gurbuz S, Dickson C, de Bono S, Schlichting D, Beattie S, Kuo WL, Rooney T, Macias W, Takeuchi T
doi: 10.1002/art.39953.
Rheumatoid Arthritis
Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis
Arthritis Res Ther.
Emery P, Tanaka Y, Cardillo T, Schlichting D, Rooney T, Beattie S, Helt C, Smolen JS
doi: 10.1186/s13075-020-02199-8.
Further Publications Rheumatology
Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis
Arthritis Res Ther
Rahman P, Mease PJ, Helliwell PS, Deodhar A, Gossec L, Kavanaugh A, Kollmeier AP, Hsia EC, Zhou B, Lin X, Shawi M, Karyekar CS, Han C
doi: 10.1186/s13075-021-02554-3